(Q36831389)

16 August 2017

Suppression of abnormal karyotype predicts superior survival in multiple myeloma (English)

1 reference

16 August 2017

0 references

4

F van Rhee

1 reference

16 August 2017

V Arzoumanian

1

1 reference

16 August 2017

A Hoering

2

1 reference

16 August 2017

J Sawyer

3

1 reference

16 August 2017

C Bailey

5

1 reference

16 August 2017

J Gurley

6

1 reference

16 August 2017

J D Shaughnessy

7

1 reference

16 August 2017

E Anaissie

8

1 reference

16 August 2017

J Crowley

9

1 reference

16 August 2017

B Barlogie

10

1 reference

16 August 2017

17 January 2008

1 reference

16 August 2017

1 reference

16 August 2017

22

1 reference

16 August 2017

4

1 reference

16 August 2017

850-855

1 reference

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.

16 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

The molecular classification of multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

International staging system for multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Evaluation of survival data and two new rank order statistics arising in its consideration

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Cytoplasmic immunoglobulin content in multiple myeloma

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Plasma cell karyotype in multiple myeloma.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Long-term outcome results of the first tandem autotransplant trial for multiple myeloma.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Thalidomide and hematopoietic-cell transplantation for multiple myeloma

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Genetics and cytogenetics of multiple myeloma: a workshop report

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3649865

Nonparametric Estimation from Incomplete Observations

5 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405091

Prognostic value of cytogenetics in multiple myeloma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.LEU.2405091

Cytogenetic findings in 200 patients with multiple myeloma

21 January 2018

1 reference

12 December 2020

Multiple myeloma: high incidence of chromosomal aneuploidy as detected by interphase fluorescence in situ hybridization

1 reference

12 December 2020

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

1 reference

12 December 2020

Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants

1 reference

12 December 2020

Total therapy with tandem transplants for newly diagnosed multiple myeloma

1 reference

12 December 2020

Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3

1 reference

12 December 2020

High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH

1 reference

12 December 2020

Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants

1 reference

12 December 2020

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

1 reference

12 December 2020

MDS-type abnormalities within myeloma signature karyotype (MM-MDS): only 13% 1-year survival despite tandem transplants

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.LEU.2405091

1 reference

release_4662wym6y5at3gzvu5galc2exu

16 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4662wym6y5at3gzvu5galc2exu

24 November 2022

mapped directly with Wikidata item

1 reference

16 August 2017

PubMed publication ID

18200039

1 reference